Data continue to show that tirzepatide, called Mounjaro for type 2 diabetes and Zepbound for weight loss, is safe and effective, but side effects remain.
— New clinical trial results on the diabetes and obesity drug tirzepatide have doctors buzzing about its potential to treat heart failure, keep weight off and prevent type 2 diabetes.
“Those are very valuable results,” says Daniel Drucker, an endocrinologist at the University of Toronto. Scientists knew that tirzepatide could cause substantial weight loss, but “delaying the onset of diabetes is also a benefit,” he says.New results from the other study, a clinical trial called SUMMIT, suggest tirzepatide can help some people with heart failure. The trial included people whose hearts squeeze normally but have trouble filling with blood.
In the trial, researchers enrolled more than 700 obese people with the heart failure condition. Those on the drug were less likely to die of cardiovascular causes or have their heart failure condition worsen compared with people taking the placebo. Those problems occurred in 36 of 364 patients taking tirzepatide, or 10 percent, versus 56 of 367 patients, or 15 percent, in the placebo group.
Other results from the SUMMIT tirzepatide trial have starting to capture a picture of what’s happening. MRI images taken before participants started taking the drug show that their hearts are heavy, and also swaddled in fat, Christopher Kramer, chief of cardiology at the University of Virginia in Charlottesville reported at the meeting and in the
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, ZepboundEli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
Read more »
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, ZepboundEli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
Read more »
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, ZepboundEli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
Read more »
Wegovy vs. Zepbound: New Data Declares a WinnerPeople taking the weight loss drug Zepbound experienced dramatically greater weight loss than competitor Wegovy in the first head-to-head trial.
Read more »
Nurse's death linked to weight-loss drug Mounjaro approved on NHSSusan McGowan from North Lanarkshire died two weeks after taking the drug tirzepatide, brand name Mounjaro.
Read more »
Zepbound results in more weight loss than Wegovy in trial, Eli Lilly saysBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »